837 related articles for article (PubMed ID: 25355546)
1. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
2. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
[TBL] [Abstract][Full Text] [Related]
3. Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B; Bunn V; Lin J; Dong C
Stat Med; 2021 Jun; 40(14):3385-3399. PubMed ID: 33851441
[TBL] [Abstract][Full Text] [Related]
4. Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.
Li JX; Chen WC; Scott JA
J Biopharm Stat; 2016; 26(6):1056-1066. PubMed ID: 27541990
[TBL] [Abstract][Full Text] [Related]
5. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
Cellamare M; Sambucini V
Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
[TBL] [Abstract][Full Text] [Related]
6. Addressing potential prior-data conflict when using informative priors in proof-of-concept studies.
Mutsvari T; Tytgat D; Walley R
Pharm Stat; 2016; 15(1):28-36. PubMed ID: 26762570
[TBL] [Abstract][Full Text] [Related]
7. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
[TBL] [Abstract][Full Text] [Related]
8. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
Lewis RJ; Lipsky AM; Berry DA
Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
[TBL] [Abstract][Full Text] [Related]
9. Modified power prior with multiple historical trials for binary endpoints.
Banbeta A; van Rosmalen J; Dejardin D; Lesaffre E
Stat Med; 2019 Mar; 38(7):1147-1169. PubMed ID: 30360016
[TBL] [Abstract][Full Text] [Related]
10. The network meta-analytic-predictive approach to non-inferiority trials.
Schmidli H; Wandel S; Neuenschwander B
Stat Methods Med Res; 2013 Apr; 22(2):219-40. PubMed ID: 22218367
[TBL] [Abstract][Full Text] [Related]
11. Adaptive allocation for binary outcomes using decreasingly informative priors.
Sabo RT
J Biopharm Stat; 2014; 24(3):569-78. PubMed ID: 24697793
[TBL] [Abstract][Full Text] [Related]
12. Bayesian approach to noninferiority trials for proportions.
Gamalo MA; Wu R; Tiwari RC
J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
[TBL] [Abstract][Full Text] [Related]
13. Sample size re-estimation incorporating prior information on a nuisance parameter.
Mütze T; Schmidli H; Friede T
Pharm Stat; 2018 Mar; 17(2):126-143. PubMed ID: 29181869
[TBL] [Abstract][Full Text] [Related]
14. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
Sambucini V
J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
[TBL] [Abstract][Full Text] [Related]
15. Quantification of prior impact in terms of effective current sample size.
Wiesenfarth M; Calderazzo S
Biometrics; 2020 Mar; 76(1):326-336. PubMed ID: 31364156
[TBL] [Abstract][Full Text] [Related]
16. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors.
Mayo MS; Gajewski BJ
Control Clin Trials; 2004 Apr; 25(2):157-67. PubMed ID: 15020034
[TBL] [Abstract][Full Text] [Related]
17. Historical controls in clinical trials: a note on linking Pocock's model with the robust mixture priors.
Callegaro A; Galwey N; Abellan JJ
Biostatistics; 2023 Apr; 24(2):443-448. PubMed ID: 37057610
[TBL] [Abstract][Full Text] [Related]
18. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
Holzhauer B; Wang C; Schmidli H
Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
[TBL] [Abstract][Full Text] [Related]
19. Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.
Gamalo MA; Tiwari RC; LaVange LM
Pharm Stat; 2014; 13(1):25-40. PubMed ID: 23913880
[TBL] [Abstract][Full Text] [Related]
20. Borrowing strength from external trials in a meta-analysis.
Higgins JP; Whitehead A
Stat Med; 1996 Dec; 15(24):2733-49. PubMed ID: 8981683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
